ConductScience.org, home

Paper392087

Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.

Chedid L and 2 others. J Reticuloendothel Soc, 1979. Cited by 62 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. Papers, record 392087. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/392087

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
PubMed
Journal
J Reticuloendothel Soc
PubMed
Year
1979
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
62
iCite
Relative citation ratio, by iCite
2.26
iCite
Revised in PubMed
2008-11-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chedid LL
2Carelli CC
3Audibert FF

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acetylmuramyl-Alanyl-IsoglutamineMajor topic
Adjuvants, ImmunologicMajor topic
Antibody FormationMajor topic
GlycopeptidesMajor topic
Immunity, CellularMajor topic
Animals
Antigens
Chemical Phenomena
Chemistry
Fever
Liposomes
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.

PMIDTitleJournalYearIn PapersSource
21299227Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives.J Med Chem2011https://conductscience.org/library/papers/21299227PubMed
17422948Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium.Can Vet J1988https://conductscience.org/library/papers/17422948PubMed
7035868Muramyl peptides. Chemical structure, biological activity and mechanism of action.Mol Cell Biochem1981https://conductscience.org/library/papers/7035868PubMed
6940181Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6940181PubMed
6777304Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines.Infect Immun1980https://conductscience.org/library/papers/6777304PubMed
6608216Anti-inflammatory effects of muramyl dipeptide in experimental models of acute inflammation.Agents Actions1984https://conductscience.org/library/papers/6608216PubMed
6566601Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6566601PubMed
6365745Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites.Immunology1984https://conductscience.org/library/papers/6365745PubMed
6352008Macrophages in cancer metastases and their relevance to metastatic growth.Cancer Metastasis Rev1983https://conductscience.org/library/papers/6352008PubMed
6284643In vivo induction of anti-herpes simplex virus immune response by type 1 antigens and lipid A incorporated into liposomes.Infect Immun1982https://conductscience.org/library/papers/6284643PubMed
3876287Degradation of muramyl dipeptide by mammalian serum.Infect Immun1985https://conductscience.org/library/papers/3876287PubMed
3867329Prevention of oncogenic viral infections in mice with CGP 11637, a synthetic muramyl dipeptide analog.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3867329PubMed
3396025In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes.Cancer Immunol Immunother1988https://conductscience.org/library/papers/3396025PubMed
3302929Liposomes in treatment of infectious diseases.Pharm Weekbl Sci1987https://conductscience.org/library/papers/3302929PubMed
3244663Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.Pharm Res1988https://conductscience.org/library/papers/3244663PubMed
1997424Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits.Infect Immun1991https://conductscience.org/library/papers/1997424PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/392087

GET https://conductscience.org/api/papers/v1/392087/authors